Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Oscar Rodas

Internal Medicine Jacksonville, FL Medical Doctor

NPI 1528002748 CMS profile 68837

1201 Monument Rd Ste 200, Jacksonville, FL 32225

Open in the dashboard

General payments

$7,864

357 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Oscar Rodas of Jacksonville, FL is reported in the CMS Open Payments database as having received $7,864 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $386 21
2024 General $755 40
2023 General $1,057 51
2022 General $1,529 67
2021 General $2,115 87
2020 General $473 31
2019 General $1,549 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oscar Rodas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Oscar Rodas were reported at $386. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Oscar Rodas Internal Medicine median Middle half National median
2019 $1,549 $159 $48–$570 $163
2020 $473 $119 $33–$402 $114
2021 $2,115 $135 $37–$521 $132
2022 $1,529 $141 $42–$496 $149
2023 $1,057 $149 $45–$519 $160
2024 $755 $154 $47–$537 $164
2025 $386 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,155 54 payments
  2. AstraZeneca Pharmaceuticals LP $929 38 payments
  3. Janssen Pharmaceuticals, Inc $830 19 payments
  4. Lilly USA, LLC $517 33 payments
  5. AbbVie, Inc. $439 32 payments
  6. Amgen Inc. $326 21 payments
  7. Pfizer Inc. $296 18 payments
  8. Dexcom, Inc. $291 9 payments
  9. Abbott Laboratories $281 9 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $277 10 payments
  11. Other $2,522 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,864 357 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $651 26 payments
  2. Ozempic $600 33 payments
  3. XARELTO $565 16 payments
  4. RYBELSUS $540 28 payments
  5. MOUNJARO $336 20 payments
  6. Repatha $308 20 payments
  7. SPRAVATO $266 3 payments
  8. FreeStyle Libre 2 $251 7 payments
  9. Otezla $250 16 payments
  10. UBRELVY $203 16 payments
  11. Other $5,724 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

5,844

Median for Internal Medicine: 777

Drug cost

$285,145

Median for Internal Medicine: $73,373

Branded share of claims

20.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 94 $57,659
Ozempic Semaglutide Brand 26 $32,676
Januvia Sitagliptin Phosphate Brand 36 $31,073
Tradjenta Linagliptin Brand 17 $14,130
Xarelto Rivaroxaban Brand 12 $11,481
Trulicity Dulaglutide Brand 11 $9,862
Fentanyl Generic 12 $6,071
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 173 $5,694
Synthroid Levothyroxine Sodium Brand 38 $5,062
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 54 $4,615

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$368,014

Of which drugs: $1,213

Medicare patients

370

Average age 76

Services billed

5,791

208 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 40%
Chronic kidney disease 39%
Ischemic heart disease 37%
Depression 28%
Atrial fibrillation 23%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,145

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $69
$69 — —
Veozah
  • Astellas Pharma US Inc $68
$68 — —
UBRELVY
  • AbbVie, Inc. $64
$64 — —
RYBELSUS
  • Novo Nordisk Inc $51
$51 — —
Ozempic
  • Novo Nordisk Inc $51
$51 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record